Cadila interested in expanding business in J&K: Modi

Excelsior Correspondent

Chairman-cum-MD Cadila Pharmaceuticals Dr Rajiv Modi interacting with media persons at Samba on Wednesday. —Excelsior/Rakesh

SAMBA, Sept 25: Cadila Pharmaceuticals which has set up its unit at Industrial Growth Centre here in 2006 has come to invest in this sensitive State with a national spirit.
This was stated by Chairman & Managing Director of the Cadila Pharmaceuticals, Dr Rajiv Modi who is on a visit to the Industrial Unit Samba while interacting with media persons today.
Flanked by J P Parswani, Executive Director of the Company and R R Chowksi Plant Head Jammu, Dr Modi appealed other investors to come to the State and set up their industrial units here with a national spirit.
Maintaining that J&K is an important State for Cadila, from business point of view, he said the company has liked the State and it wants to expand the business here.
He said that if Government provides the company more space at Samba Industrial Growth Centre where some industrial units have been closed, it will expand its business further in the State and possibly double it.
Dr Modi said that except the high technical staff majority of the workers in the Cadila Pharmaceuticals at Samba are local and the Company pays a good salary to them.
He said Cadila not only manufactures high quality medicines but it works with passion to bring something innovative.
He said the company crossed 1000 crore mark last year and it is growing every year. The mantra for the progress of the company set by its founder chairman I A Modi to offer quality medicines at affordable rates and the company will strictly stick to this philosophy, he added.
He said the industry is all set to take a quantum leap by introducing new and innovative drugs in the global market in near future.
Maintaining that Cadila Pharmaceuticals has been a research oriented company right from its inception, he said the company is investing heavily in research activities targeting the key therapeutic areas like Tuberculosis, various types of cancer, novel vaccine adjutants, sepsis management and therapeutic vaccine for pancreatic cancer.
Dr Modi said the Company has one of the best Research and Development (R&D) setups in India, manned by more than 350 scientists and engineers from various disciplines including biology, pharmacology, clinical research, chemistry, toxicology, phytochemistry and different disciplines of engineering.